167 related articles for article (PubMed ID: 22554477)
1. Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma.
Thomasson M; Hedman H; Ljungberg B; Henriksson R
BMC Res Notes; 2012 May; 5():216. PubMed ID: 22554477
[TBL] [Abstract][Full Text] [Related]
2. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT--PCR and immunohistochemical analysis.
Thomasson M; Hedman H; Guo D; Ljungberg B; Henriksson R
Br J Cancer; 2003 Oct; 89(7):1285-9. PubMed ID: 14520461
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase expression profile in clear cell renal cell carcinoma.
Behbahani TE; Thierse C; Baumann C; Holl D; Bastian PJ; von Ruecker A; Müller SC; Ellinger J; Hauser S
World J Urol; 2012 Aug; 30(4):559-65. PubMed ID: 21969129
[TBL] [Abstract][Full Text] [Related]
4. ErbB4 is downregulated in renal cell carcinoma--a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family.
Thomasson M; Hedman H; Junttila TT; Elenius K; Ljungberg B; Henriksson R
Acta Oncol; 2004; 43(5):453-9. PubMed ID: 15360049
[TBL] [Abstract][Full Text] [Related]
5. The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma.
Faragalla H; Youssef YM; Scorilas A; Khalil B; White NM; Mejia-Guerrero S; Khella H; Jewett MA; Evans A; Lichner Z; Bjarnason G; Sugar L; Attalah MI; Yousef GM
J Mol Diagn; 2012 Jul; 14(4):385-92. PubMed ID: 22580180
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical value of SALL4 in renal cell carcinomas.
Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
[TBL] [Abstract][Full Text] [Related]
7. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-inducible factor-2alpha mRNA expression in human renal cell carcinoma.
Sandlund J; Ljungberg B; Wikström P; Grankvist K; Lindh G; Rasmuson T
Acta Oncol; 2009; 48(6):909-14. PubMed ID: 19322701
[TBL] [Abstract][Full Text] [Related]
9. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.
Douglas ML; Richardson MM; Nicol DL
Cancer; 2004 May; 100(10):2118-24. PubMed ID: 15139053
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
11. Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7.
Amare Kadam PS; Varghese C; Bharde SH; Narasimhamoorthy NK; Desai S; Advani SH; Havaldar R; Kulkarni JN
Cancer Genet Cytogenet; 2001 Mar; 125(2):139-46. PubMed ID: 11369057
[TBL] [Abstract][Full Text] [Related]
12. Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy.
Zaman S; Hajiran A; Coba GA; Robinson T; Madanayake TW; Segarra DT; Chobrutskiy BI; Boyle TA; Zhou JM; Kim Y; Mulé JJ; Teer JK; Manley BJ
Eur Urol Focus; 2021 Mar; 7(2):373-380. PubMed ID: 31901438
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma.
Hirota E; Yan L; Tsunoda T; Ashida S; Fujime M; Shuin T; Miki T; Nakamura Y; Katagiri T
Int J Oncol; 2006 Oct; 29(4):799-827. PubMed ID: 16964377
[TBL] [Abstract][Full Text] [Related]
14. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
[TBL] [Abstract][Full Text] [Related]
15. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line.
Guo D; Han L; Shu K; Chen J; Lei T
J Huazhong Univ Sci Technolog Med Sci; 2007 Feb; 27(1):91-4. PubMed ID: 17393120
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinicopathological parameters with FoxM1 expression in renal cell carcinoma.
Kocarslan S; Guldur ME; Ekinci T; Ciftci H; Ozardali HI
J Cancer Res Ther; 2014; 10(4):1076-81. PubMed ID: 25579557
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
19. LDLR promotes growth and invasion in renal cell carcinoma and activates the EGFR pathway.
Zhang GM; Chen W; Yao Y; Luo L; Sun LJ
Neoplasma; 2022 Jan; 69(1):113-122. PubMed ID: 34846158
[TBL] [Abstract][Full Text] [Related]
20. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
